

cancer for administration to a human female subject comprising selecting an agent based on its ability to upregulate TGF- $\beta$  expression in the ovarian epithelium by testing said agent by treating ovarian epithelial cells through exposure to said agent and determining the resulting expression of TGF- $\beta$  in the treated ovarian epithelial cells.

*C1 cont*

2. The method of claim 1 wherein said agent is a progestin product.
3. The method of claim 2 wherein said ovarian epithelial cells are treated with said agent using an *in vivo* test.
4. The method of claim 2 wherein said test is conducted *in vitro*.
5. The method of claim 2 wherein said measured TGF- $\beta$  expression is upregulation of TGF- $\beta$  2 or TGF- $\beta$  3.
6. The method of claim 5 further comprising formulating a regimen wherein said regimen comprises a daily dosage of said composition for use by human female subject.

*C2*

MARKED CLAIMS:

1. (Amended) A method of formulating a [regimen] composition for preventing epithelial ovarian cancer for administration to a human female subject comprising selecting an agent based on its ability to upregulate TGF- $\beta$  expression in the ovarian epithelium by testing said agent by treating ovarian epithelial cells through exposure to said agent and determining the resulting expression of TGF- $\beta$  in the treated ovarian epithelial cells.
3. (New) The method of claim 2 wherein said ovarian epithelial cells are treated with said agent using an *in vivo* test--
4. (New) The method of claim 2 wherein said test is conducted *in vitro*.
5. (New) The method of claim 2 wherein said measured TGF- $\beta$  expression is